Keith T Schmidt

Pharmacist/Pharmacologist/Cancer Researcher at the National Cancer Institute - My views are my own.

[Keith T Schmidt @Keith_T_Schmidt]

"Impact factor abandoned by Utrecht University in hiring and promotion decisions" https://t.co/YJEZJX2g47

[Nature Reviews Urology @NatRevUrol]

#NEWinNRU @Keith_T_Schmidt Alwin D. R. Huitema, Cindy H. Chau & @WilliamFigg1 discuss resistance to second-generation androgen receptor antagonists in #ProstateCancer in a new Review https://t.co/fqYCw6H09E

[@gulleyj1 @gulleyj1]

Delighted that the Moderna #COVID19 #vaccine result looks so promising. Hoping our @moderna_tx vaccine trial for #cancer patients will be open soon. @EladSharonMD
https://t.co/B07oSPd43O

[Clinical Cancer Research @CCR_AACR]

Phase 1b/2a Study: BET inhibitor ZEN-3694 plus enzalutamide in mCRPC #prostatecancer.
https://t.co/U9UgYjMU9h

[UChicagoCancerCenter @UCCancerCenter]

New evidence supports the use of IL-6 antagonists against #COVID19. Read comments from Dr. Mark Ratain in @TheCancerLetter #AnswerCancer #COVIDOSE #tocilizumab https://t.co/OmyfWa7Ptd

[nature @Nature]

"We know that we should be critical as reviewers, but we are rarely taught to be kind and courteous."
https://t.co/Y9ZXSqRSHu

[Keith T Schmidt @Keith_T_Schmidt]

In our recent popPK analysis in collaboration with the Netherlands Cancer Institute in Amsterdam, we characterize the drug release from the co-polymer based nanoparticle-drug conjugate, NLG207, a drug currently under investigation at the National Cancer Institute in Maryland

[Prostate Cancer Foundation @PCFnews]

TMPRSS2, a longstanding PCF drug target, could be the key to why COVID-19 is entering the lungs. Currently, PCF is actively working on clinical trials for two different classes of anti-COVID-19 drugs. https://t.co/p5DY2aT4N4

[Keith T Schmidt @Keith_T_Schmidt]

"This multidisciplinary, consensus-driven PCA genetic implementation framework provides novel guidance to clinicians and patients tailored to the precision era. Multiple research, education, and policy needs remain of importance." https://t.co/zKJK3hg6V2

[Eric Topol @EricTopol]

Also just published @TheLancet
The 1st peer-reviewed paper of a vaccine vs #SARSCoV2 in people. 108 participants had a favorable neutralizing antibody and T cell response. Safe. Phase 1. https://t.co/twIug3Jyy1

[Keith T Schmidt @Keith_T_Schmidt]

The #APbiology hashtag is bringing back old high school memories. For the students out there, relax - we all thought it was hard 15 years ago too. People still got a 5 on it. It's ironic that some students, like cancer researchers, have focused their attention on SIRT3...

[Keith T Schmidt @Keith_T_Schmidt]

"... apalutamide plus abiraterone + prednisone was well tolerated and showed evidence of antitumor activity ... No clinically significant PK interaction was observed between abiraterone & apalutamide; however, apalutamide decreased exposure to prednisone"

https://t.co/8H8aMobGvG

[NEJM @NEJM]

Data on 8910 patients hospitalized with a diagnosis of #COVID19 were analyzed. Neither the use of angiotensin-converting–enzyme inhibitors nor the use of angiotensin-receptor blockers was associated with an increased risk of in-hospital death.

[Meg Tirrell @megtirrell]

Dr Fauci shared some details from the NIAID remdesivir study just now in the Oval Office, per pool report:

Primary endpoint of trial was time to improvement-
11 days on remdesivir vs 15 days on placebo
Fauci: “quite good news”

[Nazli Dizman @NazliDizman]

Great presentation by Dr. Padmanee Sharma of @MDAndersonNews @AACR #AACR20 on why PD-1 and PD-L1 inhibitors performed poorly in #mCRPC to date and what the next steps should be

[NEJM @NEJM]

Up to 30% of patients with metastatic castration-resistant prostate cancer have deleterious mutations in genes involved in homologous recombination repair of DNA damage. The use of the PARP inhibitor olaparib in such patients was associated with longer progression-free survival.

[Ravi A Madan M.D. @Dr_RaviMadan]

"This trial provides a cautionary tale... In developing nextgen AR-targeted therapy heretofore underappreciated neurocognitive toxicity may be a significant limitation despite promising preclinical rationale"

#Seviteronel #ProstateCancer

https://t.co/PRlRZWmuY8